{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:39:39Z","timestamp":1790109579212,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013955","name":"Astellas Pharma, Netherlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jpurol.2019.12.012","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T11:29:31Z","timestamp":1577446171000},"page":"180.e1-180.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies"],"prefix":"10.1016","volume":"16","author":[{"given":"Israel","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Hoebeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Baka-Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bolong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon N.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Dahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snijder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Stroosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verheggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Newgreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vande Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2019.12.012_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/nau.22751","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society","volume":"35","author":"Austin","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.12.012_bib2","series-title":"Targeted literature review of neurogenic detrusor overactivity in pediatric populations","author":"Astellas Pharma Europe R&D","year":"2009"},{"key":"10.1016\/j.jpurol.2019.12.012_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00467-008-0764-7","article-title":"Neurogenic bladder: etiology and assessment","volume":"23","author":"Bauer","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/816274","article-title":"Neurogenic bladder","volume":"2012","author":"Dorsher","year":"2012","journal-title":"Adv Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","article-title":"The neurogenic bladder: medical treatment","volume":"23","author":"Verpoorten","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/nau.22248","article-title":"International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children","volume":"31","author":"Rawashdeh","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.12.012_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/nau.22911","article-title":"Treatment of daytime urinary incontinence: a standardization document from the International Children's Continence Society","volume":"36","author":"Chang","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.12.012_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1464-410x.2001.02152.x","article-title":"Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida","volume":"87","author":"Ferrara","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.jpurol.2019.12.012_bib9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jpeds.2009.01.074","article-title":"Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases","volume":"155","author":"Gish","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpurol.2019.12.012_bib10","unstructured":"Vesicare 5mg film-coated tablets: summary of product characteristics (13 December 2013), https:\/\/www.medicines.org.uk\/emc\/product\/5559 [accessed 16 October 2019]."},{"key":"10.1016\/j.jpurol.2019.12.012_bib11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016718","article-title":"Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach","volume":"6","author":"Kessler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jpurol.2019.12.012_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/nau.22945","article-title":"Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study","volume":"36","author":"Amarenco","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.12.012_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2016.08.061","article-title":"Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial","volume":"71","author":"Newgreen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.juro.2017.05.038","article-title":"Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder","volume":"198","author":"Newgreen","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5489\/cuaj.1356","article-title":"Long-term use of solifenacin in pediatric patients with overactive bladder: extension of a prospective open-label study","volume":"8","author":"Nadeau","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.jpurol.2019.12.012_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-5347(06)00305-3","article-title":"The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society","volume":"176","author":"Nev\u00e9us","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib19","series-title":"Guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2013"},{"key":"10.1016\/j.jpurol.2019.12.012_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(10)62226-X","article-title":"Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies","volume":"377","author":"Fleming","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpurol.2019.12.012_bib21","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. National Center for Health Statistics. Vital Health Stat 11 2002."},{"key":"10.1016\/j.jpurol.2019.12.012_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.ju.0000147813.28822.d2","article-title":"Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction","volume":"173","author":"Franco","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sc.2013.19","article-title":"Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics","volume":"51","author":"Madersbacher","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.jpurol.2019.12.012_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5347(17)54449-3","article-title":"Prognostic value of urodynamic testing in myelodysplastic patients","volume":"126","author":"McGuire","year":"1981","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib25","first-page":"20","article-title":"Urodynamics in normal infants and children","volume":"114","author":"Hj\u00e4lm\u00e5s","year":"1988","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"10.1016\/j.jpurol.2019.12.012_bib26","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.juro.2009.06.058","article-title":"Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity","volume":"182","author":"Cartwright","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1464-410X.2004.05055.x","article-title":"Measurement of bladder compliance can be standardized by a dimensionless number: clinical perspective","volume":"94","author":"Wahl","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.jpurol.2019.12.012_bib28","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0022-5347(17)35727-0","article-title":"A new technique for dynamic analysis of bladder compliance","volume":"150","author":"Gilmour","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2019.12.012_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/nau.21129","article-title":"Bladder compliance what does it represent: can we measure it, and is it clinically relevant?","volume":"30","author":"Wyndaele","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpurol.2019.12.012_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sc.2012.164","article-title":"Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion","volume":"51","author":"Krebs","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.jpurol.2019.12.012_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14740330903260790","article-title":"Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg","volume":"8","author":"Wesnes","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpurol.2019.12.012_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.108.136390","article-title":"In\u00a0vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment","volume":"325","author":"Maruyama","year":"2008","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147751311930436X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147751311930436X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:47:36Z","timestamp":1761486456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147751311930436X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S147751311930436X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2019.12.012","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2019.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company.","name":"copyright","label":"Copyright"}]}}